Stock Events

X.T.L. Biopharmaceuticals 

€0.72
0
+€0+0% Today

Statistics

Day High
0.72
Day Low
0.72
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
4.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.15
-0.1
-0.05
0
Expected EPS
0
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow H2K2.F. It's not an investment recommendation.

About

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Show more...
CEO
Mr. Shlomo Spokone Shalev
Country
US
ISIN
US98386D3070
WKN
000A2DK34

Listings